Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Exclusion Criteria

• •Uterine leiomyosarcoma and endometrial stromal sarcomas are excluded.
• •Participants who are candidates for curative-intent therapy at the time of study enrollment.
• •Participants eligible for rechallenge with platinum-based chemotherapy as determined by the investigator.
• •Received any prior treatment with a Trop-2-directed antibody-drug conjugate (ADC).
• •Have an active second malignancy.
• •Have an active serious infection requiring systemic antimicrobial therapy.
• •Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months prior to randomization.
• •Have a positive serum pregnancy test or are breastfeeding for participants who are assigned female at birth.